PMID- 25615253
OWN - NLM
STAT- MEDLINE
DCOM- 20150615
LR  - 20181202
IS  - 1677-6119 (Electronic)
IS  - 1677-5538 (Linking)
VI  - 40
IP  - 6
DP  - 2014 Nov-Dec
TI  - Activity and safety of sunitinib in poor risk metastatic renal cell carcinoma 
      patients.
PG  - 835-41
LID - 10.1590/S1677-5538.IBJU.2014.06.16 [doi]
AB  - PURPOSE: To assess the activity, safety and treatment patterns of sunitinib in 
      patients with poor-risk metastatic renal cell carcinoma (mRCC). MATERIALS AND 
      METHODS: We retrospectively reviewed the charts of poor risk patients treated 
      with sunitinib from October 2006 to July 2013 who met the eligibility criteria. 
      The primary endpoint was overall survival (OS). Tumor radiological response was 
      measured according to RECIST 1.1 and adverse events (AEs) were assessed through 
      standard criteria. RESULTS: Median OS was 8.16 months (95% CI, 5.73-10.59). Of 
      the 53 patients included in this analysis, 9 (17.0%) achieved partial response, 
      12 (22.6%) had stable disease. Median treatment duration was 3.30 months (95% CI: 
      1.96-4.63) and 26.4% of patients discontinued treatment due to toxicity. Grade 3 
      or higher AEs occurred in 39.6% of patients, the most common being fatigue 
      (15.1%), neutropenia (9.5%), nausea, vomiting and diarrhea (7.5% each). 
      DISCUSSION: Sunitinib may benefit some unselected poor-risk patients, although 
      the rates of AEs and drug discontinuation suggest a need for careful patient 
      monitoring.
FAU - Barroso-Sousa, Romualdo
AU  - Barroso-Sousa R
AD  - Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina, Universidade 
      de Sao Paulo, Sao Paulo, Brazil.
FAU - Munhoz, Rodrigo R
AU  - Munhoz RR
AD  - Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina, Universidade 
      de Sao Paulo, Sao Paulo, Brazil and Centro de Oncologia, Hospital Sirio-Libanes, 
      Sao Paulo, Brazil.
FAU - Mak, Milena P
AU  - Mak MP
AD  - Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina, Universidade 
      de Sao Paulo, Sao Paulo, Brazil.
FAU - Fonseca, Leonardo G
AU  - Fonseca LG
AD  - Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina, Universidade 
      de Sao Paulo, Sao Paulo, Brazil.
FAU - Fede, Angelo B S
AU  - Fede AB
AD  - Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina, Universidade 
      de Sao Paulo, Sao Paulo, Brazil.
FAU - Linck, Rudinei Diogo Marques
AU  - Linck RD
AD  - Centro de Oncologia, Hospital Sirio-Libanes, Sao Paulo, Brazil.
FAU - Coelho, Clovis R
AU  - Coelho CR
AD  - Departament of Radiology and Oncology, Faculdade de Medicina, Universidade de Sao 
      Paulo, Sao Paulo, Brazil.
FAU - Moniz, Camila M V
AU  - Moniz CM
AD  - Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina, Universidade 
      de Sao Paulo, Sao Paulo, Brazil.
FAU - Souza, Ciro E
AU  - Souza CE
AD  - Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina, Universidade 
      de Sao Paulo, Sao Paulo, Brazil and Centro de Oncologia, Hospital Sirio-Libanes, 
      Sao Paulo, Brazil.
FAU - Dzik, Carlos
AU  - Dzik C
AD  - Instituto do Cancer do Estado de Sao Paulo, Faculdade de Medicina, Universidade 
      de Sao Paulo, Sao Paulo, Brazil and Centro de Oncologia, Hospital Sirio-Libanes, 
      Sao Paulo, Brazil.
LA  - eng
PT  - Journal Article
PL  - Brazil
TA  - Int Braz J Urol
JT  - International braz j urol : official journal of the Brazilian Society of Urology
JID - 101158091
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Indoles)
RN  - 0 (Pyrroles)
RN  - V99T50803M (Sunitinib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Agents/*therapeutic use
MH  - Carcinoma, Renal Cell/*drug therapy/mortality/pathology/secondary
MH  - Drug-Related Side Effects and Adverse Reactions
MH  - Female
MH  - Humans
MH  - Indoles/*therapeutic use
MH  - Kaplan-Meier Estimate
MH  - Kidney Neoplasms/*drug therapy/mortality/pathology
MH  - Male
MH  - Middle Aged
MH  - Pyrroles/*therapeutic use
MH  - Retrospective Studies
MH  - Risk Assessment
MH  - Risk Factors
MH  - Sunitinib
MH  - Time Factors
MH  - Treatment Outcome
EDAT- 2015/01/24 06:00
MHDA- 2015/06/16 06:00
CRDT- 2015/01/24 06:00
PHST- 2014/02/05 00:00 [received]
PHST- 2014/05/03 00:00 [accepted]
PHST- 2015/01/24 06:00 [entrez]
PHST- 2015/01/24 06:00 [pubmed]
PHST- 2015/06/16 06:00 [medline]
AID - IBJUv40n6a16 [pii]
AID - 10.1590/S1677-5538.IBJU.2014.06.16 [doi]
PST - ppublish
SO  - Int Braz J Urol. 2014 Nov-Dec;40(6):835-41. doi: 
      10.1590/S1677-5538.IBJU.2014.06.16.